TG103
A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity
CSPC Baike (Shandong) Biopharmaceutical Co · Phase 2 · Completed · Enrollment 314
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| TG103 7.5 mg | Obesity or overweight | 7.5 mg | 24 | n/r | n/r |
| Placebo 7.5 mg | Obesity or overweight | 7.5 mg | 24 | n/r | n/r |
| TG103 15 mg | Obesity or overweight | 15 mg | 24 | n/r | n/r |
| Placebo 15 mg | Obesity or overweight | 15 mg | 24 | n/r | n/r |
| TG103 22.5 mg | Obesity or overweight | 22.5 mg | 24 | n/r | n/r |
| Placebo 22.5 mg | Obesity or overweight | 22.5 mg | 24 | n/r | n/r |